Objective
Control of tuberculosis depends on vaccination, case finding and treatment. The most cost-effective approach to control of any infectious diseases is vaccination. However, current BCG vaccine for tuberculosis is not universally effective and interferes with
diagnosis (case finding). New vaccines and diagnostic reagents are urgently required for tuberculosis control. Traditional approaches to identification of bacterial proteins for vaccines and diagnosis depends on identification of proteins produced by the pathogen during growth in laboratory media. However, many of the most immunogenic protein antigens, that may be useful as vaccines and/or diagnostic reagents, are produced only during infection of the host. This project will utilise recent developments of molecular genetics to identify and isolate genes encoding antigens that are expressed only during infection. We will then engineer non-pathogenic mycobacteria to produce these antigenic proteins in the laboratory. The protein antigens will be tested as potential vaccines in animal models (mice and guinea pigs) by the industrial partner who has the appropriate expertise for these studies. The antigens will also be tested as reagents for diagnosis by screening infected individuals and tuberculous patients for immunoreactivity against antigens.
This project involves 5 partners from 4 different European countries who have complementary expertise (genetics, biochemistry, immunology and protection tests) and includes one industrial partner, Pasteur Mérieux Sérum et Vaccins who has expertise in the development of vaccines and reagents of medical interest.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75724 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.